The objective of this observational, single-center, retrospective study conducted in a Spanish tertiary hospital was to describe the real-world (RW) healthcare resource utilization (HCRU) among patients with advanced non-small-cell lung cancer (aNSCLC) who received chemotherapy (CT) or immunotherapy (IT) as first and second lines of treatment. A total of 173 patients diagnosed with aNSCLC and treated between January 2016 and August 2020 were included. The standardized average costs per patient/year were EUR 40,973.2 and EUR 22,502.4 for first-line CT and IT and EUR 140,601.3 and EUR 20,175.9 for second-line CT and IT, respectively. The average annual costs per patient associated with adverse-event (AE) onset were EUR 29,939.7 and EUR 460.7 for first-line CT and IT and EUR 35,906.4 and EUR 3206.1 for second-line CT and IT, respectively. The costs associated with disease management were EUR 33,178.0 and EUR 22,448.4 for first-line CT and IT and EUR 127,134.2 and EUR 19,663.9 for second-line CT and IT, respectively. In conclusion, IT use showed a lower average annual cost per patient, which was associated with lower HCRU for both disease and AE management, compared to the use of CT. However, these results should be further confirmed in the context of the currently implemented treatment schemes, including the combination of CT with single or dual IT.
本研究为一项在西班牙某三级医院开展的观察性、单中心、回顾性研究，旨在描述接受化疗或免疫疗法作为一线及二线治疗的晚期非小细胞肺癌患者在真实世界中的医疗资源使用情况。研究共纳入2016年1月至2020年8月期间确诊并接受治疗的173例晚期非小细胞肺癌患者。标准化人均年费用显示：一线化疗与免疫治疗分别为40,973.2欧元和22,502.4欧元，二线化疗与免疫治疗分别为140,601.3欧元和20,175.9欧元。与不良事件发生相关的人均年费用在一线化疗与免疫治疗中分别为29,939.7欧元和460.7欧元，在二线治疗中分别为35,906.4欧元和3,206.1欧元。疾病管理相关费用在一线化疗与免疫治疗中分别为33,178.0欧元和22,448.4欧元，在二线治疗中分别为127,134.2欧元和19,663.9欧元。结论表明，与化疗相比，免疫治疗的人均年费用更低，这与疾病管理和不良事件处理所需的医疗资源消耗减少相关。但该结果需在当前实施的包含化疗联合单药或双药免疫治疗方案背景下进一步验证。
肿瘤(癌症)患者之家